Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in its own shares conducted on August 14, 2025. The filing was submitted on August 15, 2025. The transaction was executed through Merrill Lynch International under a non-discretionary agreement established on June 4, 2025, as part of the Company's existing share buyback programme.
Key Financial Metrics and Transaction Details
- Shares Purchased: 501,689 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,401.50 GBp; highest price paid was 1,415.50 GBp.
- Average Price: Volume-weighted average price paid was 1,407.59 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Share Holdings: Following this purchase, GSK holds 241,840,788 ordinary shares in treasury.
- Shares in Issue: 4,073,550,458 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.94% of the total voting rights.
- Cumulative Buyback: Since June 4, 2025, the Company has purchased 23,706,405 ordinary shares.
Material Changes
The filing details a reduction in the number of shares in issue and an increase in treasury shares held by the Company. There are no material changes to revenue, profit, cash flow, or debt reported in this specific filing, as it is a disclosure of a capital transaction rather than a financial results report.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the Company's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025. No new guidance or outlook was provided in this document.
Investor Verification Checklist
- Verify the total number of treasury shares held (241,840,788) against the total voting rights (4,073,550,458) to confirm the 5.94% attribution.
- Confirm the cumulative volume of shares purchased since the June 4, 2025 agreement (23,706,405 shares).
- Review the "Risk Factors" section in the 2024 Form 20-F and Q2 2025 results for context on the buyback programme's impact on capital structure.
- Check the volume-weighted average price (1,407.59 GBp) against the prevailing market price on August 14, 2025.